Dr. Ho on First-Line TKI Monotherapy in mRCC

Thai H. Ho, MD, PhD
Published: Tuesday, Nov 12, 2019



Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).
 
The phase II CABOSUN trial demonstrated an improvement in progression-free survival (PFS) and overall survival with cabozantinib (Cabometyx) versus sunitinib in patients with poor- or intermediate-risk disease. In the phase III CheckMate-214, KEYNOTE-426, and JAVELIN Renal 101 trials, investigators reported at least a PFS benefit compared with sunitinib with the combinations of ipilimumab (Yervoy)/nivolumab (Opdivo), pembrolizumab (Keytruda)/axitinib (Inlyta), and axitinib/avelumab (Bavencio), respectively, in patients with advanced RCC. 
 
As such, sunitinib should not be considered for first-line treatment of mRCC, says Ho. Though, the CABOSUN data suggest that cabozantinib could be an option for patients who are intolerant of or ineligible for immunotherapy, concludes Ho.
 
SELECTED
LANGUAGE


Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).
 
The phase II CABOSUN trial demonstrated an improvement in progression-free survival (PFS) and overall survival with cabozantinib (Cabometyx) versus sunitinib in patients with poor- or intermediate-risk disease. In the phase III CheckMate-214, KEYNOTE-426, and JAVELIN Renal 101 trials, investigators reported at least a PFS benefit compared with sunitinib with the combinations of ipilimumab (Yervoy)/nivolumab (Opdivo), pembrolizumab (Keytruda)/axitinib (Inlyta), and axitinib/avelumab (Bavencio), respectively, in patients with advanced RCC. 
 
As such, sunitinib should not be considered for first-line treatment of mRCC, says Ho. Though, the CABOSUN data suggest that cabozantinib could be an option for patients who are intolerant of or ineligible for immunotherapy, concludes Ho.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x